Drug Profile
BMS 820132
Alternative Names: BMS820132Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (PO, Capsule)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (PO, Liquid)
- 28 Apr 2011 Bristol Myers-Squibb initiates enrolment in a phase I trial for Type 2 diabetes mellitus in USA (NCT01290575)